According to the Zhitong Finance App, Laikai Pharmaceutical-B (02105.HK) announced interim results for the six months ended June 30, 2026. The group obtained additional revenue of 259.62 million yuan (RMB, same below), an increase of 30.41% year on year; R&D expenses of 97 million yuan, a decrease of 7.79% year on year; loss of 2.54 million yuan during the period, a decrease of 98.03% year on year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.